Business Club News, January 14
Looking back on the drug market in 2010, it is more likely that the price of medicinal herbs will double or rise. Medicinal materials have almost entered the "inflation" market.
After many years of low-cost accumulation, natural disasters have become more and more difficult, artificially reluctant sellers, hoarding, and large amounts of hot money have entered, and many factors have been exerting themselves. The price of herbal medicine has naturally risen.
At the end of the year, the drug market has returned to calm and prices have risen at a high level. The huge changes that have taken place in the drug market in the past year still leave many questions worth pondering. The author has screened and sorted out 50 species of medicinal herbs as the representative species for price hikes in 2010 and made a summary and analysis.
After the rise, there were 12 varieties that were stable: Morinda officinalis, gardenia, Amomum villosum, Liaowuwei, Bitter Almond, Zanthoxylum bungeanum, Psoralea, Ginger, Arisaema, Poria, Angelica, and Poria. Although some of these varieties have high prices, but due to many years of low prices, production has been greatly reduced, some suffer severe natural disasters, and inventory is not large, it is expected that with the actual market digestion, the future price of a few varieties still have room to rise .
Prices continue to rise in seven varieties: heterophylla, Bupleurum, glutinous rice, Gastrodia, Pinellia, Ophiopogon japonicus, home peach kernel. The prices of heterophylla, glutinous rice, and home peach kernels are already high. However, due to tight supply, the market will remain high in the short term; after the actual market digestion and adjustment of Bupleurum, Tianma and Pingbei, the market outlook still has potential for growth. .
After the rise, there were 31 species that fell back: Panax ginseng, honeysuckle, bergamot, Pinellia ternate, Platycodon grandiflora, turmeric, Sassafras purpurea, red ginseng, Codonopsis pilosula, northern Adenophora, Polygala, Alisma, Zhebei, Yuanhu, Galangal, Chuanxiong, white peony root, paeonol, white peony root, purple peony root, Atractylodes macrocephala, Plantago, star anise, grass fruit, hawthorn meat, Anemarrhena, Coix seed, Polygala, Sterculia lychnophora, water Pinellia, Gualou. After the prices of the above varieties increased, they fell back, mainly because middlemen had low-priced goods in their hands. Some of these varieties have a tendency to rise as prices rise, and they do not have enough power to raise prices. There is no room for price increases in the short term.
Some medicines have risen as prices have risen, and production has begun to recover, and is showing an increase trend. These varieties will return to a reasonable price as the market actually digests. Of course, some of them are expected to see new changes in the market after the production has not yet been widely developed.
The drastic changes in the drug market in 2010 will be the overall improvement of the drug market, and will be the same as the time when the medicinal material's own value and the overall economic development of the society. The price increase of medicinal herbs in 2010 was not only the accumulation of low prices for many years, but also the disconnection of the medicinal product production chain. In 2010, the long-term low price of raw herbs was ended. At present, the drug market seems to have entered the “inflation†period. In fact, most of the medicines origins are not sourced, and the stocks of pharmaceutical companies are also relatively weak. After a high level of shock adjustment, the drug market in the new year is still ahead.
Looking back on the drug market in 2010, it is more likely that the price of medicinal herbs will double or rise. Medicinal materials have almost entered the "inflation" market.
After many years of low-cost accumulation, natural disasters have become more and more difficult, artificially reluctant sellers, hoarding, and large amounts of hot money have entered, and many factors have been exerting themselves. The price of herbal medicine has naturally risen.
At the end of the year, the drug market has returned to calm and prices have risen at a high level. The huge changes that have taken place in the drug market in the past year still leave many questions worth pondering. The author has screened and sorted out 50 species of medicinal herbs as the representative species for price hikes in 2010 and made a summary and analysis.
After the rise, there were 12 varieties that were stable: Morinda officinalis, gardenia, Amomum villosum, Liaowuwei, Bitter Almond, Zanthoxylum bungeanum, Psoralea, Ginger, Arisaema, Poria, Angelica, and Poria. Although some of these varieties have high prices, but due to many years of low prices, production has been greatly reduced, some suffer severe natural disasters, and inventory is not large, it is expected that with the actual market digestion, the future price of a few varieties still have room to rise .
Prices continue to rise in seven varieties: heterophylla, Bupleurum, glutinous rice, Gastrodia, Pinellia, Ophiopogon japonicus, home peach kernel. The prices of heterophylla, glutinous rice, and home peach kernels are already high. However, due to tight supply, the market will remain high in the short term; after the actual market digestion and adjustment of Bupleurum, Tianma and Pingbei, the market outlook still has potential for growth. .
After the rise, there were 31 species that fell back: Panax ginseng, honeysuckle, bergamot, Pinellia ternate, Platycodon grandiflora, turmeric, Sassafras purpurea, red ginseng, Codonopsis pilosula, northern Adenophora, Polygala, Alisma, Zhebei, Yuanhu, Galangal, Chuanxiong, white peony root, paeonol, white peony root, purple peony root, Atractylodes macrocephala, Plantago, star anise, grass fruit, hawthorn meat, Anemarrhena, Coix seed, Polygala, Sterculia lychnophora, water Pinellia, Gualou. After the prices of the above varieties increased, they fell back, mainly because middlemen had low-priced goods in their hands. Some of these varieties have a tendency to rise as prices rise, and they do not have enough power to raise prices. There is no room for price increases in the short term.
Some medicines have risen as prices have risen, and production has begun to recover, and is showing an increase trend. These varieties will return to a reasonable price as the market actually digests. Of course, some of them are expected to see new changes in the market after the production has not yet been widely developed.
The drastic changes in the drug market in 2010 will be the overall improvement of the drug market, and will be the same as the time when the medicinal material's own value and the overall economic development of the society. The price increase of medicinal herbs in 2010 was not only the accumulation of low prices for many years, but also the disconnection of the medicinal product production chain. In 2010, the long-term low price of raw herbs was ended. At present, the drug market seems to have entered the “inflation†period. In fact, most of the medicines origins are not sourced, and the stocks of pharmaceutical companies are also relatively weak. After a high level of shock adjustment, the drug market in the new year is still ahead.
Smart thermometer,ear thermometer,best baby thermometer,forehead thermometer
Shenzhen urion Technology Co., Ltd. , https://www.urionhealth.com